ROS1 and non-small cell lung carcinoma: According the statement paper of International Association for the Study of Lung Cancer (IASLC), a positive EGFR, ALK, ROS1, or BRAF result of liquid biopsy NGS should be considered adequate to initiate first-line therapy in advanced NSCLC, however, a negative results requires a confirmation from tumor biopsy (20).